Redcliffe Lifetech is a private company building in healthcare, founded in 2017. Its most recent disclosed valuation is $150M. Its shares do not trade on a public exchange.
One company valuation: $150M.
LeapFrog InvestmentsLEADIIFULEADHHealthquadSSchrodersLLC NuevaGGrowth Spark VenturesCChiratae VenturesAAlkemi Venture PartnersLeapFrog InvestmentsIFURedcliffe Lifetech, known publicly as Redcliffe Labs, is an Indian diagnostics company founded in 2018 and based in Noida, India. It runs an omni-channel diagnostics service across more than 200 cities, offering over 3,600 pathology tests through a network of more than 1,700 collection centres and more than 70 labs. The group also carries the Redcliffe Hygiene and Crysta IVF brands.
Roughly 65% of Redcliffe's customers are classified as low-income consumers living on less than $11.20 a day, and its tests are priced 25 to 60% below incumbent operators. The company positions itself around bringing affordable diagnostics to India's smaller cities as much as its metros.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Redcliffe Lifetech.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Redcliffe Lifetech availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Redcliffe Lifetech included.
The closest healthcare peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Redcliffe Lifetech is a private company; its shares do not trade on a public exchange.
The last valuation is $150M.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
